Honzík T, Tesarová M, Hansíková H, Krijt J, Benes P, Zámecník J, Wenchich L, Zeman J
Klinika detského a dorostového lékarství 1 LF UK a VFN, Praha.
Cas Lek Cesk. 2006;145(8):665-70.
Mitochondrial neurogastrointestinal encephalomyopathy (MNGIE) is a disorder with autosomal recessive inheritance caused by mutations in the gene encoding thymidine phosphorylase (TP). TP deficiency results in imbalance of mitochondrial pool of nucleotides leading secondary to multiple deletions and depletion of mitochondrial DNA (mtDNA) and impairment of oxidative phosphorylation system. The disease is clinically characterized by gastrointestinal dysmotility with symptoms of pseudo-obstruction, severe failure to thrive, ptosis, leukoencephalopathy, peripheral neuropathy and myopathy. We present results of the clinical, histochemical, biochemical and molecular analyses of the first Czech patient with MNGIE syndrome.
Man, 33-years old with twenty-year history of failure to thrive (height 168 cm, weight 34 kg) and progressive gastrointestinal dysmotility, external ophthalmoplegia, leucoencephalopathy and peripheral neuropathy was recommended to metabolic center. Histochemical analyses in muscle biopsy showed the presence of "ragged red fibers" with focal decrease of cytochrome c oxidase activity, but spectrophotometric analyses in isolated muscle mitochondria revealed normal activities of all respiratory chain complexes. Metabolic investigation revealed markedly increased plasma level of thymidine (6.6 micromol/l, controls <0.05 micromol/l) and deoxyuridine (15 micromol/l, controls <0.05 micromol/l). The activity of TP in isolated lymphocytes was low (0.02 micromol/hour/mg protein, reference range 0.78 +/- 0.18). Molecular analyses in muscle biopsy revealed multiple mtDNA deletions and homozygous mutation 1419G>A (Gly145Arg) was found in gene for TP. Both parents are heterozygotes.
MNGIE has to be considered in patients presenting with a combination of gastrointestinal and neurological symptoms. Plasma level of thymidine may serve as the best method for laboratory screening of MNGIE, but molecular analyses are necessary for genetic counselling and prenatal diagnosis in affected families.
线粒体神经胃肠性脑肌病(MNGIE)是一种常染色体隐性遗传疾病,由胸苷磷酸化酶(TP)编码基因突变引起。TP缺乏导致线粒体核苷酸池失衡,继而引发线粒体DNA(mtDNA)的多处缺失和耗竭以及氧化磷酸化系统受损。该疾病的临床特征为胃肠动力障碍,伴有假性肠梗阻症状、严重发育不良、上睑下垂、白质脑病、周围神经病变和肌病。我们展示了首例捷克MNGIE综合征患者的临床、组织化学、生物化学及分子分析结果。
一名33岁男性,有20年发育不良病史(身高168厘米,体重34千克),伴有进行性胃肠动力障碍、眼外肌麻痹、白质脑病和周围神经病变,被转诊至代谢中心。肌肉活检的组织化学分析显示存在“破碎红纤维”,细胞色素c氧化酶活性局部降低,但分离的肌肉线粒体的分光光度分析显示所有呼吸链复合物的活性正常。代谢研究显示血浆胸苷水平显著升高(6.6微摩尔/升,对照组<0.05微摩尔/升)和脱氧尿苷水平升高(15微摩尔/升,对照组<0.05微摩尔/升)。分离淋巴细胞中TP的活性较低(0.02微摩尔/小时/毫克蛋白,参考范围0.78±0.18)。肌肉活检的分子分析显示存在多处mtDNA缺失,并且在TP基因中发现纯合突变1419G>A(Gly145Arg)。父母双方均为杂合子。
对于出现胃肠和神经症状组合的患者,必须考虑MNGIE。血浆胸苷水平可作为MNGIE实验室筛查的最佳方法,但对于受影响家庭的遗传咨询和产前诊断,分子分析是必要的。